Smith Jeffrey T. L. - 12 Jan 2026 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Reporting relationship: EVP & Chief Medical Officer
Issuer ticker: ZYME
Reported as of: 12 Jan 2026
Net transaction value: -$211,090
SEC form: 4
Accepted by SEC: 12 Jan 2026, 21:00:11 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Smith Jeffrey T. L. filed Form 4 for Zymeworks Inc. (ZYME) on 12 Jan 2026.

Key facts

This page summarizes Smith Jeffrey T. L.'s Form 4 filing for Zymeworks Inc. (ZYME).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jan 2026, 21:00.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: -$211,090.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001604800 Primary reporting owner

Smith Jeffrey T L

Relationship: EVP & Chief Medical Officer
Address: C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Signature: /s/ Daniel Dex, Attorney-in-Fact
Signature date: 12 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZYME transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +17,666
Change %: +96%
Price: $0.000000
Shares after: 36,018
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F1

ZYME transaction

Common Stock

Sale

Transaction value: $211,090
Shares: -9,310
Change %: -26%
Price: $22.67
Shares after: 26,708
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -17,666
Change %: -33%
Price: $0.000000
Shares after: 35,334
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,666
Exercise price
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025.

Footnote F2

Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F4

Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

Footnote F5

The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.